IL-23 was first described by Robert Kastelein and colleagues at the DNAX research institute using a combination of
computational,
biochemical and cellular
immunology approaches.[1]
IL-23 is mainly secreted by activated
dendritic cells,
macrophages or
monocytes. Innate lymphoid cells and γδ T cells also produce IL-23.[2]B cells produce IL-23 through
B cell antigen receptor signaling.[8] Secretion is stimulated by an antigen stimulus recognised by a
pattern recognition receptor.[9] IL-23 imbalance and increase is associated with
autoimmune diseases and
cancer. It is thus a target for therapeutic research.[4] IL-23 expression by dendritic cells is further induced by
thymic stromal lymphopoietin, a proallergic cytokine expressed by keratinocytes that is elevated in psoriatic lesions.[10] In the pathogenesis of psoriasis, dermal dendritic cells are stimulated to release IL-23 by nociceptive neurons.[11] IL-23 is also elevated during bacterial meningitis, leading to epithelial dysregulation and inflammation.[12]
Prior to the discovery of IL-23,
IL-12 had been proposed to represent a key mediator of
inflammation in mouse models of inflammation.[14] However, many studies aimed at assessing the role of IL-12 by pharmacological blockade had targeted IL-12B, and were therefore not as specific as thought. Studies which blocked the function of
IL-12A did not produce the same results as those targeting IL-12B, as would have been expected if both
subunits formed part of IL-12 only.[15]
The discovery of an additional potential binding partner for IL-12B led to a reassessment of this role for IL-12. Studies in
experimental autoimmune encephalomyelitis, a mouse model of
multiple sclerosis, showed that IL-23 was responsible for the inflammation observed, not IL-12 as previously thought.[16] Subsequently, IL-23 was shown to facilitate development of inflammation in numerous other models of immune pathology where IL-12 had previously been implicated, including models of
arthritis,[17] intestinal inflammation,[18][19][20] and
psoriasis.[21] Low concentrations of IL-23 support lung tumor growth whereas high concentrations inhibit proliferation of lung cancer cells.[22] IL-23 and IL-23R were identified in serum from patients with non-small-cell lung cancer and have been proposed as prognostic serum markers.[23] IL-23 can also promote progression of cardiovascular diseases such as atherosclerosis, hypertension, aortic dissection, cardiac hypertrophy, myocardial infarction and acute cardiac injury[citation needed]. In brain, IL-23 is able to activate γδ T cells to increase their expression of IL-17, which contributes to the inflammatory response and thus plays a key role in secondary brain injury after spontaneous intracerebral hemorrhage.[24]
Monoclonal antibody drugs
IL-23 is one of the therapeutic targets to treat the inflammatory diseases.[25]Ustekinumab, a monoclonal antibody directed against this cytokine, is used to treat certain autoimmune conditions.[26]Guselkumab is another monoclonal antibody against IL-23. Blocking IL-23 can slow clinical manifestation of psoriasis, indirectly affecting Th17 immune response and production of IL-17.[27]Ixekizumab, an IL-17A antagonist, has been reported to have faster onset of action in treatment of psoriasis than guselkumab,
tildrakizumab or
risankizumab, which are inhibitors of the p19 subunit of IL-23.[28] However, risankizumab has been shown to have the best treatment results for psoriasis in comparison with other IL-23 inhibitors.[29]Adnectin-2 binds to IL-23 and competes with IL-23–IL-23R binding.[25]
Signalling
The IL-23 heterodimer binds the receptor complex: the p19 subunit binds IL-23R while the p40 subunit binds IL-12RB1. Receptor binding leads to recruitment of
Janus kinase 2 and
Tyrosine kinase 2 kinases.
Janus kinase 2 and
Tyrosine kinase 2 transduce the signal and phosphorylate
STAT3 and
STAT4. STATs dimerise and activate transcription of target genes in nucleus.
STAT3 is responsible for key
Th17 development attributes such as
RORγt expression and transcription of
Th17cytokines.[4]
^Li Y, Wang H, Lu H, Hua S (2016). "Regulation of Memory T Cells by Interleukin-23". International Archives of Allergy and Immunology. 169 (3): 157–62.
doi:
10.1159/000445834.
PMID27100864.
S2CID24274565.
^Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, Seymour B, et al. (February 2003). "Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain". Nature. 421 (6924): 744–8.
Bibcode:
2003Natur.421..744C.
doi:
10.1038/nature01355.
PMID12610626.
S2CID4380302.
^Zhu H, Wang Z, Yu J, Yang X, He F, Liu Z, Che F, Chen X, Ren H, Hong M, Wang J (March 2019). "Role and mechanisms of cytokines in the secondary brain injury after intracerebral hemorrhage". Prog. Neurobiol. 178: 101610.
doi:
10.1016/j.pneurobio.2019.03.003.
PMID30923023.
S2CID85495400.